Printer Friendly

BIOGEN APPOINTS LAWRENCE S. DANIELS VICE PRESIDENT-MARKETING AND BUSINESS DEVELOPMENT

     BIOGEN APPOINTS LAWRENCE S. DANIELS VICE PRESIDENT-MARKETING
                    AND BUSINESS DEVELOPMENT
    CAMBRIDGE, Mass., Nov. 6 /PRNewswire/ -- Biogen, Inc. (NASDAQ: BGEN) announced today the appointment of Lawrence S. Daniels as vice president-marketing and business development.  He will assume worldwide responsibility for Biogen's business development, strategic planning and general commercial activities.
    Daniels joins Biogen from Allied Signal, Inc., in Morristown, N.J., where he had been vice president, corporate strategy development since 1986.  From 1982-1986, Daniels was senior vice president, planning and administration for the Allied Health & Scientific Products Company, a health care business group of Allied Signal.  Before joining Allied, Daniels held various senior planning and corporate development positions with several major firms, including Abbott Laboratories, where he was vice president, corporate planning and development.
    Daniels succeeds Alan Tuck who recently resigned to pursue a career outside of Biogen.
    James L. Vincent, Biogen chairman and chief executive officer, commented, "Larry's extensive strategic planning and corporate development experience, including more than eight years in the health care industry, makes him eminently qualified to assume this most important senior management position at Biogen.  The creation of sound strategy is the foundation that a company like Biogen is built on.  Larry and I have worked together twice before on similar missions and he has few peers as a strategic thinker."
    Daniels received his B.S. in mechanical engineering from Princeton University and both an M.S. in mechanical engineering and an M.S. in management from Massachusetts Institute of Technology.
    Biogen, Inc., headquartered in Cambridge, Mass., is a biopharmaceutical company principally engaged in developing and manufacturing drugs for human health care through genetic engineering. The company's revenues are generated from the worldwide sales by licensees of five products, including alpha interferon, hepatitis vaccines and hepatitis diagnostic products.  Biogen is focused primarily on developing and testing products used for the treatment of cardiovascular disease, inflammatory diseases, AIDS and certain cancers.
    -0-                     11/6/91
    /CONTACT:  John W. Catterall of Biogen, 617-252-9897/
    (BGEN) CO:  Biogen, Inc. ST:  Massachusetts IN:  MTC SU:  PER KM-SH -- NE011 -- 1700 11/06/91 12:18 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 6, 1991
Words:344
Previous Article:ANNE H. MCNAMARA NAMED TO BOARD OF DIRECTORS OF LG&E ENERGY AND LOUISVILLE GAS AND ELECTRIC
Next Article:XSCRIBE CORP. ANNOUNCES SECOND QUARTER RESULTS
Topics:


Related Articles
BIOGEN ANNOUNCES APPOINTMENT OF MICHAEL J. ASTRUE AS VICE PRESIDENT AND GENERAL COUNSEL
BIOGEN ANNOUNCES MANAGEMENT REALIGNMENT AS NEXT STEP IN TRANSITION FROM R&D ORGANIZATION TO OPERATING COMPANY

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters